TapImmune Inc. (TPIV)

10.13 -0.27 (-2.596%)

IEX Real-Time Price

July 16, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 10.4

Price Open 10.37

Volume: 176,991

Avg Volume: 1.09M

Market Cap: 129.33M

P/E Ratio -

52 Wk Range 2.58-13.55



TPIV Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-06-15
7.68M
522,613
0.41
6.81%

2018-05-31
7.68M
60,481
0.18
0.79%

2018-05-15
7.68M
48,899
1.19
0.64%

2018-04-30
5.54M
37,921
1.01
0.68%




News

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status (2018-07-05 14:46 SeekingAlpha)

Galectin Therapeutics (NASDAQ: GALT ) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise …

 


Statistics

Shares Outstanding: 12.77M

Top 15 Institution Percent: 29.70

Price To Sales: N/A

Price To Book: 215.56

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -235.29

Return On Equity: -434.86

Profit Margin: N/A

Price History

Beta: -0.34

50-day Moving Avg: 6.71

200-day Moving Avg: 4.13

YTD Change: 155.53

5-day Change: 2.97

1-month Change: -15.65

3-month Change: N/A

6-month Change: 184.93

1-year Change: N/A

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: TapImmune Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.tapimmune.com

TapImmune Inc is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The company's next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches.